FIGURE

Fig. 6

ID
ZDB-FIG-220727-48
Publication
Jeong et al., 2022 - Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders
Other Figures
All Figure Page
Back to All Figure Page
Fig. 6

CKD-504 is an efficient HDAC6 inhibitor that repairs NMJ defects.

(A) Lateral view images after staining with anti-SV2 and α-BTX of a whole-mounted zebrafish injected with control or gars MOs, or treated with CKD-504 or FDA-approved drugs. The merged images are magnified from the images in the rectangular regions. Scale bars = 50 μm. (B-D) Comparisons of presynapse (B), postsynapse (C), and NMJ (D) signal ratios within the ROI among zebrafish embryos injected with control MOs (n = 29), gars MOs (n = 17), gars MOs with vorinostat (n = 18), pomiferin (n = 41), or CKD-504 (n = 18). Statistical significance was assessed using one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. ns, non-significant. (E and F) Comparison of NMJ innervation in the presynaptic area (E) and postsynaptic (F) areas among zebrafish embryos injected with control MOs (n = 24); gars MOs (n = 22); and gars MOs with vorinostat (n = 16), pomiferin (n = 36), and CKD-504 (n = 36). Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. ns, non-significant.

Expression Data
Antibody:
Fish:
Conditions:
Knockdown Reagent:
Anatomical Terms:
Stage: Protruding-mouth

Expression Detail
Antibody Labeling
Phenotype Data
Fish:
Conditions:
Knockdown Reagent:
Observed In:
Stage: Protruding-mouth

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Mol. Cells